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Abstract
Background: After focal brain injuries occur, in addition to the effects that are attributable to the primary site of
damage, the resulting functional impairments depend highly on changes that occur in regions that are remote but
functionally connected to the site of injury. Such effects are associated with apoptotic and inflammatory cascades
and are considered to be important predictors of outcome. Repetitive transcranial magnetic stimulation (rTMS) is a
noninvasive technique that is used to treat various central nervous system (CNS) pathologies and enhance
functional recovery after brain damage.
Objective: This study examined the efficacy of rTMS in mitigating remote degeneration and inflammation and in
improving functional recovery in a model of focal brain damage.
Methods: Rats that were undergoing hemicerebellectomy (HCb) were treated with an rTMS protocol for 7 days,
and neuronal death indices, glial activation, and functional recovery were assessed.
Results: rTMS significantly reduced neuronal death and glial activation in remote regions and improved functional
recovery.
Conclusions: Our finding opens up a completely new scenario for exploiting the potential of rTMS as an
anti-apoptotic and anti-inflammatory treatment.
Keywords: Transcranial magnetic stimulation, Inflammation, Apoptosis, Remote degeneration, Glial activation,
Neuroprotection
Introduction
The changes that arise at the primary lesion site after a
brain focal lesion occurs account for a small fraction of
the plastic reorganization that is needed for a good func-
tional outcome [1]. Alterations in regions that are re-
mote to the primary damage are critical [1, 2]. Notably,
structural and molecular changes in these remote areas
are sustained by many factors, including apoptosis and
inflammation [2], for which various pharmacological ap-
proaches have been proposed [2].
Repetitive transcranial magnetic stimulation (rTMS) is
a noninvasive and easily tolerated method that changes
the excitability at the site of stimulation and produces
widespread effects at the network level [3, 4], with thera-
peutic potential for a broad range of neurological and
psychiatric disorders [5–10]. Although it has been im-
plemented clinically in many CNS pathologies, the cellu-
lar and molecular substrates that underlie the effects of
rTMS remain poorly understood [11]. Among the differ-
ent mechanisms involved, inflammation is one of the
possible targets of rTMS effects, although little is ana-
lyzed up to now.
The present study addresses the effects of rTMS on re-
mote degenerative mechanisms, such as apoptotic cell
death and glial activation, induced by hemicerebellect-
omy (HCb) [12]. The HCb paradigm is a reliable and
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effective model for examining remote damage mecha-
nisms and providing a testing ground for novel neuropro-
tective approaches. In this model, neuronal degeneration




The experimental protocol was approved by the Italian
Ministry of Health (permit number: 444/2015-PR) and
conformed to the EU Directive 2010/63/EU for the
care and use of laboratory animals. All efforts were
made to minimize the number of animals used and
their suffering.
Animals, surgery, and rTMS treatment
Fifty-six male Wistar rats (150–200 g) were used. For
surgical procedures, the rats were deeply anesthetized by
i.p. injections of xylazine (Rompun; 10 mg/ml; Bayer)
and tiletamine and zolazepam (Zoletil 100; 50 mg/ml;
Virbac) and the right cerebellar hemisphere was re-
moved as previously described [13]. For the control
(Ctrl) group, surgery was interrupted after the dura inci-
sion. One hour after surgery, the animals received theta-
burst stimulation or sham stimulation (regular coil
switched off ) by positioning the rat so that the posterior
portion of the head was accessible. The coil was held
close to the skull between the ears, corresponding to the
occipital bone where the wound was sutured, and 10
trains of 50-Hz bursts (3 pulses), repeated at 5 Hz, were
applied in 10-s intervals (300 pulses) using a DuoMAG™
XT-100 rTMS through a 70-mm butterfly coil
(DEYMED Diagnostic s.r.o., Czech Republic). Stimulus
strength was set to 30 % of maximum device output. In
the following days, the rats (sham and rTMS) were
lightly sedated during treatment. Stimulation was ap-
plied daily for 7 days (Additional file 1: Figure S1) by an
investigator blind of the experimental group (lesioned vs
unlesioned animals).
Histological procedures and stereological analysis
One hour after the last rTMS treatment, anesthetized
animals were perfused transcardially as previously de-
scribed [13]. Brains were cut using a freezing microtome,
and sections were collected in phosphate buffer (PB).
One series of brain sections was Nissl-stained [13], while
the remaining two series were incubated with a cocktail
of primary antibodies including rabbit anti-ionized cal-
cium binding adaptor molecule 1 (Iba-1; 1:400; Wako,
Japan), mouse anti-glial fibrillary acidic protein (GFAP;
1:500; Merck Millipore, Italy), mouse anti-neuronal nu-
clei (NeuN; 1:200; Merck Millipore), and goat anti-
cytochrome-c (1:400; Santa Cruz Biotechnology, USA).
After washes in PB, sections were incubated with a
cocktail of secondary antibodies as previously reported
[13]. Images were acquired on a CLSM 700 (Zeiss,
Germany). Qualitative and quantitative analyses were
limited to the pontine nuclei (Pn) of the experimental
side, and the stereological quantification was performed
as previously described [13]. Further details are reported
in Additional file 2.
Protein isolation/Western blotting
One hour after the last rTMS treatment, anesthetized
rats were sacrificed by decapitation. Pn were isolated,
homogenized, and treated as previously described [13].
Samples were incubated with the following primary anti-
bodies: rabbit anti-GFAP (1:2500; Dako, Denmark),
rabbit anti-Iba-1 (1:500; Wako, Japan), and mouse anti-
cytochrome-c (1:1000; BD Pharmingen, UK). Densities
of protein bands in the Western blots were measured,
and mean ratios between proteins and β-actin were re-
ported as percentage of control values. The relative
levels of immunoreactivity were determined by densi-
tometry using the free software ImageJ (National Insti-
tutes of Health, Bethesda, MD, USA). Further details are
reported in Additional file 2.
Quantitative real-time PCR
Quantitative real-time PCR was performed as previously
described [13]. The primers used were as follows: rat GFAP
F1 (5′-GTCTCGAATGACGCCTCCAC-3′) and rat GFAP
R1 (5′-TGTAGCTAGCAAAGCGGTCA-3′); rat Iba-1 F1
(5′-GCAAGGATTTGCAGGGAGGA-3′) and rat Iba-1 R1
(5′-CGTCTTGAAGGCCTCCAGTT-3′); and rat β-actin
F1 (5′-ATCCTGACCCTGAAGTACCC-3′) and rat β-actin
R1 (5′-AAGGTCTCAAACATGATCTGG-3′). Further
details are reported in Additional file 2.
Functional evaluation
Neurological impairment was evaluated by the neuro-
logical severity score (NSS) [13]. NSS is a composite of
motor, sensory, reflex, and balance tests, where for each
test, one point is awarded for the inability to perform or
for the lack of a tested reflex and zero points are
awarded for success. A NSS of 18 indicates severe injury,
whereas a score of zero signifies healthy, uninjured rats.
The NSS was evaluated at 1, 3, 5, and 7 days after dam-
age (5 h after TMS treatment) by an investigator who
was blind to the lesioned and unlesioned groups.
Statistical analyses
All values were expressed as mean ± s.e. All parameters
were subjected either to parametric analysis of variance
(ANOVA) or to repeated-measure ANOVA. ANOVA
was followed, in cases of significance (P < 0.05), by
post hoc comparisons using Duncan’s test. All quanti-
tative analyses were conducted blind to the animal’s
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experimental group. All statistical analyses were car-
ried out with the help of Statistica software Version
12.0 (StatSoft, Tulsa, OK, USA).
Results
Consistent with our previous results [13–15], HCb in-
duced progressive and severe neuronal death in contra-
lateral Pn 7 days after the lesion (Fig. 1a), associated
with increased cytochrome-c (cyt-c) release from dam-
aged mitochondria into the cytosol (Fig. 1b, c).
rTMS treatment significantly reduced HCb-induced
neuronal cell death in Pn (group × treatment: F[1,16] =
12.130, P < 0.003; Fig. 1a). After sham treatment, the Pn
population fell to 40 % of prelesional values, whereas after
rTMS, over 70 % of Pn neurons remained (Fig. 1a). To in-
vestigate the possible effects of rTMS treatment on the
apoptotic cascade, we analyzed the mitochondrial cyt-c re-
lease in Pn. We observed self-evident differences in cyt-c
immunostaining patterns between the HCb-rTMS and
HCb-s groups (Fig. 1b). Furthermore, by means of
mitochondrial-cytosolic fractionation, we demonstrated
that rTMS significantly reduced cyt-c release into the cyto-
sol (group × treatment: F[1,12] = 252.417, P < 0.001; Fig. 1c).
Notably, the rTMS and sham treatments were ineffective in
unlesioned rats (Fig. 1a–c).
Further, as expected [16], HCb effected intense
astrocyte and microglial activation in Pn, as evidenced
by the increasing number of GFAP- and Iba-1-positive
cells (Fig. 2a, b) and by the upregulation of GFAP and
Iba-1 messenger RNA (mRNA) and protein (Fig. 2c, d).
rTMS treatment significantly attenuated the HCb-induced
glial activation, as demonstrated by the reduction in the
total number of GFAP- and Iba-1-positive cells (GFAP,
group × treatment: F[1,196] = 444.208, P < 0.001; Iba-1,
group × treatment: F[1,196] = 595.584, P < 0.001; Fig. 2a, b)
and in GFAP and Iba-1 mRNA (GFAP, group: F[1,12] =
16.68, P < 0.002; GFAP, treatment: F[1,12] = 14.85,
P < 0.002; Iba-1, group: F[1,12] = 17.26, P < 0.001; Iba-1,
treatment: F[1,12] = 27.57, P < 0.001; Fig. 2c) and protein
(GFAP, group: F[1,12] = 27.69, P < 0.001; GFAP, treatment:
F[1,12] = 31.44, P < 0.001; Iba-1, group × treatment:
F[1,12] = 12.28, P < 0.001; Fig. 2d). No effects were ob-
served in the unlesioned groups (Fig. 2a–d).
Furthermore, rTMS significantly improved functional re-
covery, as demonstrated by the NSS test (treatment:
F[1,14] = 9.76, P < 0.007; day: F[3,42] = 46.91, P < 0.001;
Fig. 1 rTMS reduces neuronal death and cytochrome-c release in remote neurons (a). Histograms of stereological counts of Nissl-stained neurons
in pontine nuclei (Pn) expressed as experimental/Ctrl (E/C) ratio in control-sham (Ctrl-s), HCb-sham (HCb-s), control-rTMS (Ctrl-rTMS), and HCb-rTMS groups.
b NeuN (green) and cytochrome-c (cyt-c; red) double-labeling confocal images from pontine nuclei of HCb-sham and HCb-rTMS animals at 7 days after
injury showing cyt-c release into the cytosol of neurons (arrows). c Representative immunoblots and densitometric graphs of cytochrome-c release (cyt-c)
in pontine nuclei of Ctrl-s, HCb-s, Ctrl-rTMS, and HCb-rTMS groups. **P< 0.01, ***P< 0.001. Scale bars: B = 25 μm
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Fig. 2e), with rTMS inducing greater functional recovery
starting from 3 days of treatment (Fig. 2e).
Discussion
This study demonstrates that rTMS significantly reduces
mitochondrial damage, apoptotic neuronal death, and
glial activation and supports functional recovery in a rat
model of remote damage after focal cerebellar injury.
Here, we showed that rTMS significantly reduced
HCb-induced cell death of precerebellar neurons by
blocking cyt-c-associated apoptosis. These findings are
consistent with earlier reports on the anti-apoptotic ef-
fects of rTMS in the perilesional area after TBI [17] and
after transient cerebral ischemia [18]. Although remote
mechanisms differ substantially from those in perile-
sional areas after traumatic or ischemic insults [2, 12],
our data demonstrate the effectiveness of rTMS in coun-
teracting apoptotic cell death in areas that are distant
from the site of damage. Although the efficacy of rTMS
in reducing apoptotic cell death in our model is quite
specific, further mechanistic studies are required to
identify signaling pathways of rTMS effects on precere-
bellar neurons. In addition to the effects on neurons,
our data also showed that glial cells, specifically astro-
cytes and microglia, responded to rTMS stimulation. In
fact, in our model rTMS significantly reduces HCb-
induced inflammatory responses, which have been
shown to contribute to remote degeneration [2]. At
present, there is limited information regarding the re-
sponse of astrocytes and microglia to rTMS in health
and disease [19]. Present data demonstrating the rTMS
effects on neuroinflammation, although pointing to a
direct effect of TMS on glial cells, do not allow to rule
out a direct effect on neurons and their survival. Overall,
taking into account the key role of neuron-glia crosstalk
in CNS physiology and pathophysiology, the influence of
Fig. 2 rTMS reduces astrocytes and microglial activation in remote regions and improves functional recovery. a Representative confocal microscopy
images of Iba-1 positive microglial cells (red) and GFAP positive astrocytes (green) both counterstained with Dapi (blue) in pontine nuclei of HCb-sham and
HCb-rTMS groups. b Histograms of the number of Iba-1+ microglial cells and GFAP+ astrocytes in pontine nuclei in Ctrl-s, HCb-s, Ctrl-rTMS, and HCb-rTMS
groups. c Histograms of mRNA expression level of Iba-1 and GFAP in Ctrl-s, HCb-s, Ctrl-rTMS, and HCb-rTMS groups. d Representative immunoblots and
densitometric graphs of Iba-1 and GFAP protein levels in pontine nuclei of Ctrl-s, HCb-s, Ctrl-rTMS, and HCb-rTMS groups. e Time course of neurological
recovery (NSS) in the Ctrl-s, HCb-s, Ctrl-rTMS, and HCb-rTMS groups. *P< 0.05, **P< 0.01, ***P< 0.001. Scale bars: A = 100 μm
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TMS on glial cells is critical to open up novel thera-
peutic options. However, further studies are needed to
clarify the specific effect of TMS on neuron and glial
cells as well as on their crosstalk mechanisms to being
able to develop TMS approaches for modulating specific
cellular responses. In this line, it is worth considering
that in our model, as well as in many brain pathologies,
plastic responses to injury are not limited to mitochon-
drial damage or glial activation. We cannot exclude that
other factors, in addition to those mentioned, are also
sensitive to rTMS. On the other hand, as the clinical sig-
nificance and positive therapeutic effects of rTMS in a
great variety of CNS disorders suggest that they are de-
termined by a combination of multiple factors, we can
speculate that, also in our model, rTMS-mediated neu-
roprotection is a multifactorial process in which many
elements play a role. Future research on these mecha-
nisms and factors will be critical for the development of
more powerful and reliable TMS therapeutic protocols.
In particular, interactions between neurophysiological
and cellular/molecular effects of TMS represent a new
and intriguing field, which is opening up new lines of re-
search to address neuronal survival and plasticity after
CNS insults.
We are aware that the use of a commercial human-
sized coil with high-intensity field strengths (≥1 T)
might be a limitation of our study [20, 21], rendering
dose efficacy or target selectivity requirements unable to
be evaluated. However, the selectivity of the effects of
rTMS on lesion-induced changes and the patent differ-
ences between sham and rTMS treatments support the
reliability of our findings. Furthermore, the high sensitiv-
ity of the damaged tissue to rTMS is also notable. No
changes in any of our parameters were observed in the
unlesioned group.
Establishing the link between the sparing of neuronal
death in a given population and improvements in func-
tional recovery is always challenging. We cannot exclude
that rTMS, especially using so large a coil, might influ-
ence outcomes by acting on neural centers that differ
from those that we have considered. Plasticity-related
changes after rTMS can occur in regions that are func-
tionally connected to the stimulated area and thus con-
tribute to the efficacy of rTMS [22–25]. Despite these
cautions, the demonstration of cellular and molecular
changes in a key node of the cerebro-cerebellar
loop—i.e., the Pn—supports the importance of Pn sur-
vival in the recovery.
Conclusions
In conclusion, although further mechanistic studies are
required to identify detailed signal pathways of rTMS ef-
fects, our study demonstrates that the effects of TMS
are multifactorial and extend beyond the conventional
synaptic effects that are usually considered [20, 21].
These effects involve neuronal and glial-dependent
mechanisms, both of which have significance in the
pathophysiology of various neurological diseases and in
the modulation of plastic responses after injury.
These findings open new therapeutic scenarios of
paramount importance, demonstrating the potential of
rTMS as non-pharmacological approach to counteract
apoptosis and inflammation, common players in several
CNS diseases, such as stroke, traumatic brain, and spinal
cord injuries.
Additional files
Additional file 1: Figure S1. Schematic of the hemicerebellectomy
(HCb) model and of the treatment protocol employed in the study. (A)
Due to the crossed input-output organization of the cerebellar connections,
unilateral lesion of a cerebellar hemisphere induces axonal lesions
and subsequent degeneration of the contralateral (experimental side)
inferior olive (IO) and pontine nuclei (Pn), with sparing of the IO and Pn on
the ipsilateral side (control side). (B) One hour after hemicerebellectomy (HCb;
day 0), Ctrl (unlesioned rats) and HCb rats received repetitive transcranial
magnetic stimulation (rTMS) or sham stimulation (no coil activation).
Stimulation was applied daily for 7 days. DCN: deep cerebellar nuclei;
icp: inferior cerebellar peduncle. (TIFF 1031 kb)
Additional file 2: Methods supplementary material: Histological,
biochemical, and stereological approaches for pontine nuclei analyses
after hemicerebellectomy. (DOCX 19 kb)
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